Next Article in Journal
Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection
Next Article in Special Issue
Effect of Carbon Chain Length, Ionic Strength, and pH on the In Vitro Release Kinetics of Cationic Drugs from Fatty-Acid-Loaded Contact Lenses
Previous Article in Journal
Liquid Film Translocation Significantly Enhances Nasal Spray Delivery to Olfactory Region: A Numerical Simulation Study
Previous Article in Special Issue
Asymmetry in Drug Permeability through the Cornea
Article

Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease

1
Ocular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, Ireland
2
Pharmaceutical Department, UC Leuven-Limburg, Campus Gasthuisberg Herestraat 49, 3000 Leuven, Belgium
3
The Vision Clinic, R95 XC98 Kilkenny, Ireland
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Clive Prestidge
Pharmaceutics 2021, 13(6), 905; https://doi.org/10.3390/pharmaceutics13060905
Received: 31 December 2020 / Revised: 1 June 2021 / Accepted: 9 June 2021 / Published: 18 June 2021
(This article belongs to the Special Issue Recent Advances in Ophthalmic Drug Delivery)
Dry eye disease (DED) or keratoconjunctivitis sicca is a chronic multifactorial disorder of the ocular surface caused by tear film dysfunction. Symptoms include dryness, irritation, discomfort and visual disturbance, and standard treatment includes the use of lubricants and topical steroids. Secondary inflammation plays a prominent role in the development and propagation of this debilitating condition. To address this we have investigated the pilot scale development of an innovative drug delivery system using a dexamethasone-encapsulated cholesterol-Labrafac™ lipophile nanostructured lipid carrier (NLC)-based ophthalmic formulation, which could be developed as an eye drop to treat DED and any associated acute exacerbations. After rapid screening of a range of laboratory scale pre-formulations, the chosen formulation was prepared at pilot scale with a particle size of 19.51 ± 0.5 nm, an encapsulation efficiency of 99.6 ± 0.5%, a PDI of 0.08, and an extended stability of 6 months at 4 °C. This potential ophthalmic formulation was observed to have high tolerability and internalization capacity for human corneal epithelial cells, with similar behavior demonstrated on ex vivo porcine cornea studies, suggesting suitable distribution on the ocular surface. Further, ELISA was used to study the impact of the pilot scale formulation on a range of inflammatory biomarkers. The most successful dexamethasone-loaded NLC showed a 5-fold reduction of TNF-α production over dexamethasone solution alone, with comparable results for MMP-9 and IL-6. The ease of formulation, scalability, performance and biomarker assays suggest that this NLC formulation could be a viable option for the topical treatment of DED. View Full-Text
Keywords: dry eye disease; keratoconjunctivitis sicca; dexamethasone; corticosteroid; biomarker; nanostructured lipid carrier; cell studies; translational research dry eye disease; keratoconjunctivitis sicca; dexamethasone; corticosteroid; biomarker; nanostructured lipid carrier; cell studies; translational research
Show Figures

Figure 1

MDPI and ACS Style

Kumari, S.; Dandamudi, M.; Rani, S.; Behaeghel, E.; Behl, G.; Kent, D.; O’Reilly, N.J.; O’Donovan, O.; McLoughlin, P.; Fitzhenry, L. Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease. Pharmaceutics 2021, 13, 905. https://doi.org/10.3390/pharmaceutics13060905

AMA Style

Kumari S, Dandamudi M, Rani S, Behaeghel E, Behl G, Kent D, O’Reilly NJ, O’Donovan O, McLoughlin P, Fitzhenry L. Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease. Pharmaceutics. 2021; 13(6):905. https://doi.org/10.3390/pharmaceutics13060905

Chicago/Turabian Style

Kumari, Sangeeta, Madhuri Dandamudi, Sweta Rani, Elke Behaeghel, Gautam Behl, David Kent, Niall J. O’Reilly, Orla O’Donovan, Peter McLoughlin, and Laurence Fitzhenry. 2021. "Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease" Pharmaceutics 13, no. 6: 905. https://doi.org/10.3390/pharmaceutics13060905

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop